Xarelto Litigation Update

Approved in 2011, Xarelto (rivaroxaban) is one of the newest blood thinners on the market and is manufactured by Bayer and marketed in the U.S. by Johnson & Johnson’s subsidiary, Janssen Pharmaceuticals.

According to the most recent data, at least 1700 lawsuits related to Xarelto have been filed so far. Generally, these cases allege that Xarelto caused a patient to suffer from severe internal bleeding or hemorrhagic stroke. Xarelto lawsuits also allege that warning information contained on the drug’s label is inadequate and fails to convey the alleged serious and deadly side effects of Xarelto.

Xarelto is used to lower the risk of stroke and blood clot formation in patients who suffer from or are at risk for atrial fibrilation, deep vein thrombosis, and pulmonary embolism. Xarelto is considered effective at preventing blood from clotting, but as such, is alleged to pose a risk for serious bleeding. According to the lawsuits, this internal bleeding is particularly problematic because Xarelto does not have an "antidote" to counteract its anticoagulant effects. Most, if not all anti-coagulant drugs pose some bleeding risk, but Xarelto lawsuits assert that because there is no known "antidote" to Xarelto bleeding events, the drug is less safe than other blood thinners.

Because of the large number of claims already filed, the U.S. Judicial Panel on Multidistrict Litigation consolidated these cases into multidistrict litigation (MDL) in Louisiana. An MDL simplifies the legal process because many cases can be handled by the same experienced judge and in the same court.

The Xarelto "Bellwether Trials" are scheduled to begin in August of 2016. Bellwether trials, which are used as representative case studies, help determine how the entire litigation will be resolved. Two bellwether trials will take place in the Eastern District of Louisiana, one in the Southern District of Texas, and another in the Southern District of Mississippi, according to court documents.

Frohlich, Gordon & Beason, P.A. is accepting Xarelto cases. If you or a loved one have been affected by uncontrolled bleeding or any of the other dangerous side effects of Xarelto, contact our office at 941-979-9010 for a free consultation.

Firm Blogs Articles Hot Topics


our office location

Frohlich, Gordon & Beason, P.A.
18401 Murdock Circle, Suite C
Port Charlotte, FL 33948
Phone: 941-787-3289
Toll free: 800-430-6443
Fax: 941-979-9250
Map and Directions

View or download our Frohlich, Gordon & Beason, P.A Brochure

Contact Us Today!

Bold labels are required.

Contact Information

The use of the Internet or this form for communication with the firm or any individual member of the firm does not establish an attorney-client relationship. Confidential or time-sensitive information should not be sent through this form.


Privacy Policy